Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free PTGX Stock Alerts

Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume

Protagonist Therapeutics logo
$136.64 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$136.73 +0.09 (+0.07%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Protagonist Therapeutics Short Interest Overview

As of July 15, 2026, Protagonist Therapeutics (PTGX) had a short interest of 8.29 million shares sold short, representing 13.60% of the public float. This marks a 7.82% increase in short interest since the prior report. The short interest ratio (days to cover) is 9.5, meaning it would take 9.5 days of the average trading volume of 700,312 shares to cover all short positions.

Current Short Interest
8,292,656 shares
Previous Short Interest
7,691,347 shares
Change Vs. Previous Month
7.82%
Dollar Volume Sold Short
$1.12 billion
Short Interest Ratio
9.5 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
64,311,000 shares
Short Percent of Float
13.60%
Today's Trading Volume
548,760 shares
Average Trading Volume
700,312 shares
Today's Volume Vs. Average
78%
Short Selling Protagonist Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

PTGX Short Interest Over Time

PTGX Days to Cover Over Time

PTGX Percentage of Float Shorted Over Time

Protagonist Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/20268,292,656 shares $1.12 billion +7.8%13.6%9.53 $135.46
6/30/20267,691,347 shares $942.81 million -0.5%12.6%7.22 $122.58
6/15/20267,728,416 shares $869.14 million +4.3%12.7%11.59 $112.46
5/29/20267,410,849 shares $737.82 million +1.6%12.2%16.81 $99.56
5/15/20267,293,819 shares $745.28 million -3.3%12.0%12.76 $102.18
4/30/20267,540,996 shares $746.33 million -10.2%12.4%11.88 $98.97
4/15/20268,397,278 shares $885.41 million -2.7%13.8%11.61 $105.44
3/31/20268,626,880 shares $909.27 million +7.0%14.1%7.64 $105.40
3/13/20268,060,991 shares $744.51 million -1.6%13.3%10.88 $92.36
2/27/20268,192,998 shares $754.41 million -3.0%13.5%16.48 $92.08
2/13/20268,443,732 shares $688.08 million +3.8%13.8%13.31 $81.49
1/30/20268,132,629 shares $665.25 million -2.0%13.7%10.56 $81.80
1/15/20268,297,775 shares $703.24 million +13.8%14.0%8.75 $84.75
12/31/20257,292,034 shares $636.89 million +11.5%12.3%9.51 $87.34
12/15/20256,539,025 shares $619.83 million +11.2%11.0%6.01 $94.79
11/28/20255,883,017 shares $529.32 million +5.4%9.9%7.07 $89.98
11/14/20255,582,326 shares $472.32 million +2.1%9.4%5.85 $84.61
10/31/20255,465,729 shares $429.72 million -13.4%9.2%5.6 $78.62
10/15/20256,310,000 shares $490.16 million -5.0%10.7%5.8 $77.68
9/30/20256,640,000 shares $441.10 million -0.3%N/A7.8 $66.43
9/15/20256,660,000 shares $388.81 million -2.8%N/A8.1 $58.38
8/31/20256,850,000 shares $404.49 million +8.6%11.6%8.2 $59.05
8/15/20256,310,000 shares $353.80 million +9.6%N/A8 $56.07
7/31/20255,760,000 shares $310.23 million -6.8%9.7%7 $53.86
7/15/20256,180,000 shares $341.88 million -8.2%N/A7.1 $55.32
6/30/20256,730,000 shares $371.97 million +13.9%11.4%6.8 $55.27
6/15/20255,910,000 shares $333.15 million +13.4%10.0%5.8 $56.37
5/31/20255,210,000 shares $246.33 million -1.5%9.2%4.4 $47.28
5/15/20255,290,000 shares $234.93 million -13.6%9.4%4.2 $44.41
4/30/20256,120,000 shares $280.42 million +9.9%N/A5 $45.82
4/15/20255,570,000 shares $261.51 million +18.3%9.9%4.8 $46.95
3/31/20254,710,000 shares $227.78 million -8.2%8.4%4.4 $48.36
3/15/20255,130,000 shares $281.02 million +5.3%9.1%5.4 $54.78
2/28/20254,870,000 shares $183.06 million +15.4%8.6%6 $37.59
2/15/20254,220,000 shares $163.19 million +11.4%7.5%6.4 $38.67
1/31/20253,790,000 shares $143.26 million +3.3%N/A5.5 $37.80
1/15/20253,670,000 shares $139.24 million -3.4%N/A5.5 $37.94
12/31/20243,800,000 shares $146.68 million +5.3%N/A5.7 $38.60
12/15/20243,610,000 shares $148.30 million +6.2%N/A5.4 $41.08
11/30/20243,400,000 shares $148.92 million +3.0%N/A5 $43.80
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel

See the 5 stocks to avoid
11/15/20243,300,000 shares $135.66 million +0.6%N/A4.9 $41.11
10/31/20243,280,000 shares $150.36 million +9.3%N/A5.5 $45.84
10/15/20243,000,000 shares $142.92 million -14.8%N/A4.6 $47.64
9/30/20243,520,000 shares $158.40 million +9.0%N/A5.2 $45.00
9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02
8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89
8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59
7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44
7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75
6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65
6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39
5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15
5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47
4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11
4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58
3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93
3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98
2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38
2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23
1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01
1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90
12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93
12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07
11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21
11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29
10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54
10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44
9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68
9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90
8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82
8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76
7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40
7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25
6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62
6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68
5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07
5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97
4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60
4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74
3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00
3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05
2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22
2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32
1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29
1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17
12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91
12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53
11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91
11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04
10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel

👉 Unlock the ticker now and get it completely free.
10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99
9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43
9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27
8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72
8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33
7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95
7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46
6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91
6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48
5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76
5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81
4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09
4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95
3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68
3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82
2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28
2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73
1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29
1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96
12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20
12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54
11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62
11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74
10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16
10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97
9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72
9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47
8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50
8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69

PTGX Short Interest - Frequently Asked Questions

Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 8,292,656 shares of PTGX short. 13.60% of Protagonist Therapeutics' shares are currently sold short. Learn More on Protagonist Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 9.5. Learn More on Protagonist Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.60% of Protagonist Therapeutics' floating shares are currently sold short.

Protagonist Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 8,292,656 shares, an increase of 7.8% from the previous total of 7,691,347 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

13.60% of Protagonist Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Protagonist Therapeutics: Biogen Inc. (4.07%), Alnylam Pharmaceuticals, Inc. (4.36%), Incyte Corporation (6.28%), Roivant Sciences Ltd. (5.72%), BioNTech SE Sponsored ADR (1.11%), Moderna, Inc. (14.81%), United Therapeutics Corporation (5.38%), Insmed, Inc. (5.48%), Genmab A/S Sponsored ADR (1.23%), BridgeBio Pharma, Inc. (15.33%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading down $2.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like PTGX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:PTGX) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel